Biotech firm Circassia based at the Oxford Science Park, has started phase three trials of cat allergy treatment.
The new study follows encouraging results in previous trials for the ToleroMune vaccine.
Chief executive Steve Harris said: “Tens of millions of people are allergic to cats in the US and Europe, and the disease can have a major effect on patients’ quality of life.”
Comments: Our rules
We want our comments to be a lively and valuable part of our community - a place where readers can debate and engage with the most important local issues. The ability to comment on our stories is a privilege, not a right, however, and that privilege may be withdrawn if it is abused or misused.
Please report any comments that break our rules.
Read the rules hereComments are closed on this article